Blood tests predicted MS worsening or relapses on Gilenya
Key Takeaway
Two blood markers pointed to different risks for people with MS taking Gilenya: worsening without a relapse and future relapses.
What They Found
Researchers studied two blood markers in people with MS taking fingolimod (Gilenya). Higher levels of one marker were linked to worsening without a relapse, but not to future relapses. Higher levels of the other marker were linked to future relapses, but not to worsening without a relapse. Both markers fell over time while people were taking Gilenya. The marker linked to worsening stayed higher in people who later worsened without a relapse.
Who Should Care and Why
The study included people with MS taking Gilenya and healthy volunteers used for comparison. Researchers followed the people with MS for about nine years. About 31% of them had worsening without a relapse. The findings may help explain why different blood tests give different information about MS activity. The abstract does not name which forms of MS the participants had.
Important Considerations
You should know this was an observational study, not a trial testing whether Gilenya prevents worsening. It included 420 people with MS and 4,297 healthy volunteers. These links do not show that a blood test can predict what will happen to you as an individual.
AI-generated summary — for informational purposes only, not medical advice
Categories:
Article Topics:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/9/2026
A mouse study suggests prepared red blood cells may calm MS-like immune attacks. Learn why liver cel
Read More
10/9/2026
See how lab-grown nerve cells move a key protein, why this may matter for nerve health, and why the
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Brain : a journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.